A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors

Summary

This is a phase 1, open-label, single-arm, first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835 administered orally in patients with advanced solid tumors.

Timeline

Start

2021-06-28

Primary completion

2024-06-28

Completion

2024-12-28

Drugs

Indications